Yatharth Hospital Q4 FY26: Revenue up 47%, stock slips

What triggered the sharp fall in the stock

Shares of Yatharth Hospital & Trauma Care Services Ltd came under pressure in Monday’s afternoon trade soon after the company reported its March 2026 quarter (Q4 FY26) results. The stock fell as much as 7.18% to a day low of ₹801 even as the hospital chain posted strong year-on-year growth in revenue and profit. The market reaction appeared to be driven less by the headline growth and more by operating margin compression during the quarter.

Different market snapshots during the day showed the stock trading lower by varying magnitudes. One update cited a fall of 4.51% to ₹824 on the BSE, while another showed the stock at ₹829.80, down 3.84% versus the previous close of ₹862.95. The day’s trading range was reported at ₹889.80 on the high side and ₹827.40 on the low side in one feed, underscoring the volatility around the result.

Q4 FY26 headline numbers: revenue and profit expanded

For Q4 FY26, revenue from operations was reported at about ₹341.6 crore, up 47% year-on-year from ₹233 crore in Q4 FY25. On a quarter-on-quarter basis, revenue increased 6% from ₹321.4 crore in Q3 FY26. These figures point to continued scale-up in the company’s hospital operations over the last few quarters.

On the profit front, one set of numbers in the updates showed profit after tax (PAT) rising 15% year-on-year to ₹44.7 crore from ₹38.7 crore in the corresponding quarter last year. Another summary in the same material said consolidated net profit rose 23% to ₹47.5 crore on revenue of ₹341.5 crore. The difference in the profit figures indicates that multiple summaries of the results were circulating, but both versions indicate higher profitability versus the year-ago quarter.

EBITDA growth was healthy, but margins tightened

Operating performance, as measured by EBITDA, also improved in absolute terms. EBITDA was reported to have advanced 37% year-on-year and 6% quarter-on-quarter in Q4 FY26. However, the EBITDA margin fell 161 basis points to 23.4% in Q4 FY26, from 25% in Q4 FY25.

This margin contraction was highlighted as a key factor behind the stock’s decline despite the top-line growth. In hospital businesses, investors often track operating leverage and efficiency closely, so any sign of margin pressure can weigh on sentiment, even in a quarter of strong revenue growth.

Company’s adjusted margin and profit metrics

The company also provided an adjusted view of profitability to explain the margin movement. It said the EBITDA margin adjusted for ramp-up losses stood at 30.4% during the quarter. It also stated that adjusted PAT, excluding ramp-up losses, grew 23.3% year-on-year.

These adjusted numbers suggest the company is incurring costs tied to scaling operations, and management is asking investors to consider the underlying margin potential excluding ramp-up losses. Even so, the market’s immediate focus during the session appeared to remain on the reported margin contraction to 23.4%.

How the trading session played out

The post-results trading action reflected a classic “growth vs margins” trade-off. The stock hit a reported intraday low of ₹801 after being down 7.18% at one point. Separately, the stock was also reported at ₹829.80, down 3.84% compared with the last close of ₹862.95, and another update cited a 4.51% fall to ₹824 on the BSE.

Such gaps across real-time feeds can happen when different timestamps and venues are referenced. What is consistent across the updates is that the stock was materially lower on the day results were discussed, even as the quarter showed higher revenue and profit.

Key data points at a glance

Analyst ratings and peer watch

One market snapshot in the provided material stated there were 0 analysts with a “strong buy” rating and 2 analysts with a “buy” rating on the stock, and none with a “sell” rating. The same snapshot listed peers and their moves: Max Healthcare Institute (-2.15%), Apollo Hospitals Enterprise (0.55%), and Narayana Hrudayalaya (4.69%).

While peer moves on the day can vary for reasons unrelated to a single company’s results, the comparison helps contextualise that the decline in Yatharth Hospitals was notable on a day when other listed hospital names showed mixed price action.

Market impact: why margins mattered more than growth

The immediate market impact from the update was a sharp, result-linked sell-off, with the stock falling into the low ₹800s intraday. The central point of tension was that revenue growth remained strong, but EBITDA margin declined year-on-year by 161 bps to 23.4%. For investors tracking hospital operators, a margin step-down can raise near-term questions about cost inflation, ramp-up costs, and the pace at which new capacity becomes profitable.

At the same time, the company’s adjusted metrics - 30.4% adjusted EBITDA margin and 23.3% year-on-year growth in adjusted PAT excluding ramp-up losses - were positioned to show that profitability could look stronger when one-off or expansion-linked losses are excluded. The market’s initial reaction suggests investors still wanted clearer evidence of sustained reported margin improvement.

Analysis: growth is visible, operating leverage is under scrutiny

The quarter’s numbers show that Yatharth Hospitals is scaling, with revenue rising to about ₹341.6 crore in Q4 FY26 and improving sequentially from Q3 FY26. Profit also increased year-on-year in the data provided, regardless of which profit summary is used. But the reported EBITDA margin decline to 23.4% became the focal point for short-term price action.

The company’s adjusted disclosures indicate management is emphasising that ramp-up losses are affecting near-term margins. Investors typically watch whether such ramp-up periods shorten over time and whether reported margins begin to converge with adjusted margins as new units mature. For now, the session’s move indicates the market was pricing in caution around cost and margin dynamics.

Conclusion

Yatharth Hospital & Trauma Care Services’ Q4 FY26 results showed strong revenue growth and higher profit, but the stock fell sharply amid reported margin contraction to 23.4%. The company highlighted stronger adjusted profitability after excluding ramp-up losses, including an adjusted EBITDA margin of 30.4%. In the near term, investor attention is likely to remain on whether margin pressure eases in upcoming quarters, alongside continued revenue growth.